China’s CAR-T Therapy Emerging in Glioma Treatment: Neurosurgery Team Wins Three International Awards
**China’s CAR-T Therapy Emerging in Glioma Treatment: Neurosurgery Team Wins Three International Awards**
Glioma
At the recently concluded 76th International Exhibition of Ideas, Inventions, and New Products (IENA) in Nuremberg, Germany, a Chinese neurosurgery research team achieved remarkable success. Their independently developed project, the “Fourth-Generation Dual-Target Optimized CAR-T Cell Therapy Platform for Neuro-oncology,” stood out among over 500 inventions from more than 30 countries and regions. The team was awarded the exhibition’s highest prize, a gold medal, and the Best Invention Award from the International Federation of Inventors’ Associations (IFIA).
### Glioma: A New Application Area for China’s CAR-T Cell Therapy
Glioma is a malignant brain tumor resistant to traditional treatments. Its complexity and invasion into functional brain areas significantly affect patients’ quality of life and survival rates. In 2022, glioma-related deaths in China reached 57,000. Against this backdrop, CAR-T cell therapy offers a breakthrough hope in neuro-oncology.
The award-winning project by the Chinese neurosurgery team overcame a series of critical challenges, including efficient therapeutic target screening, reversing the immunosuppressive microenvironment of solid tumors, and optimizing CAR-T enhancement sequences. Based on these advancements, they developed Tris-CAR-T dual-target cell therapy. This therapy innovatively targets tumor stem cells, effectively enhancing the proliferation and killing capacity of CAR-T cells. Preliminary clinical trial results indicate that this therapy is highly effective and safe. To date, it has received nine national invention patents and eight international patents, with four of these patents already successfully commercialized.
### Global Attention and China’s Rising Technological Expertise
During the exhibition, research institutions, industry experts, and media from around the world showed great interest in this technology, considering it a milestone marking China’s CAR-T cell therapy’s advancement to an internationally leading position in neuro-oncology. The Chinese neurosurgery research team was an early leader in optimizing and expanding CAR-T therapy, which now has the potential for application in other solid tumors, showing significant clinical value and development prospects.
The IENA, founded in 1948, is one of the world’s three major invention exhibitions, showcasing top global innovations. Its fair and impartial review process provides an authoritative platform for worldwide inventions. The IFIA, as a nonprofit international inventors’ organization, aims to promote inventors’ status and facilitate international cooperation, significantly influencing global intellectual property and technological innovation.
The achievements of the Chinese neurosurgery team mark China’s accelerated rise in CAR-T cell therapy. In the future, China’s CAR-T innovations are expected to bring new hope for neuro-oncology patients globally, positioning China as a leader in this field.